These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 25596424)

  • 1. Role of Natural Killer Cells in Intravenous Immunoglobulin-Induced Graft-versus-Host Disease Inhibition in NOD/LtSz-scidIL2rg(-/-) (NSG) Mice.
    Gregoire-Gauthier J; Fontaine F; Benchimol L; Nicoletti S; Selleri S; Dieng MM; Haddad E
    Biol Blood Marrow Transplant; 2015 May; 21(5):821-8. PubMed ID: 25596424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of immunoglobulins in the prevention of GvHD in a xenogeneic NOD/SCID/γc- mouse model.
    Gregoire-Gauthier J; Durrieu L; Duval A; Fontaine F; Dieng MM; Bourgey M; Patey-Mariaud de Serre N; Louis I; Haddad E
    Bone Marrow Transplant; 2012 Mar; 47(3):439-50. PubMed ID: 21572464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Xenogeneic Graft-Versus-Host Disease in Humanized NSG and NSG-HLA-A2/HHD Mice.
    Ehx G; Somja J; Warnatz HJ; Ritacco C; Hannon M; Delens L; Fransolet G; Delvenne P; Muller J; Beguin Y; Lehrach H; Belle L; Humblet-Baron S; Baron F
    Front Immunol; 2018; 9():1943. PubMed ID: 30214443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective treatment against severe graft-versus-host disease with allele-specific anti-HLA monoclonal antibody in a humanized mouse model.
    Nakauchi Y; Yamazaki S; Napier SC; Usui J; Ota Y; Takahashi S; Watanabe N; Nakauchi H
    Exp Hematol; 2015 Feb; 43(2):79-88.e1-4. PubMed ID: 25448490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of acute xenogeneic graft- versus-host disease, but retention of T-cell function following engraftment of human peripheral blood mononuclear cells in NSG mice deficient in MHC class I and II expression.
    Brehm MA; Kenney LL; Wiles MV; Low BE; Tisch RM; Burzenski L; Mueller C; Greiner DL; Shultz LD
    FASEB J; 2019 Mar; 33(3):3137-3151. PubMed ID: 30383447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of human IL-2-activated natural killer and T cells on graft-versus-host disease and graft-versus-leukemia in SCID mice bearing human leukemic cells.
    Xun CQ; Thompson JS; Jennings CD; Brown SA
    Transplantation; 1995 Oct; 60(8):821-7. PubMed ID: 7482742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Xenogeneic graft-versus-host-disease in NOD-scid IL-2Rγnull mice display a T-effector memory phenotype.
    Ali N; Flutter B; Sanchez Rodriguez R; Sharif-Paghaleh E; Barber LD; Lombardi G; Nestle FO
    PLoS One; 2012; 7(8):e44219. PubMed ID: 22937164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Establishment of an xenogeneic acute graft-versus-host disease model in NOD/SCID mice by engraftment of G-CSF mobilized human mononuclear cells].
    Gao L; Wang JM; Xie LN; Zhou H; Qiu HY
    Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):87-91. PubMed ID: 18681307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humanized Chronic Graft-versus-Host Disease in NOD-SCID il2rγ-/- (NSG) Mice with G-CSF-Mobilized Peripheral Blood Mononuclear Cells following Cyclophosphamide and Total Body Irradiation.
    Fujii H; Luo ZJ; Kim HJ; Newbigging S; Gassas A; Keating A; Egeler RM
    PLoS One; 2015; 10(7):e0133216. PubMed ID: 26176698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of bone marrow-derived mesenchymal stromal cells on experimental xenogeneic graft-versus-host disease.
    Bruck F; Belle L; Lechanteur C; de Leval L; Hannon M; Dubois S; Castermans E; Humblet-Baron S; Rahmouni S; Beguin Y; Briquet A; Baron F
    Cytotherapy; 2013 Mar; 15(3):267-79. PubMed ID: 23265769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of cyclosporin A on interleukin-15-activated umbilical cord blood natural killer cell function.
    Lin SJ; Kuo ML
    Cytotherapy; 2008; 10(4):397-405. PubMed ID: 18574772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety analysis of ex vivo-expanded canine natural killer cells in a xenogeneic mouse model of graft-versus-host disease.
    Kim CJ; Park SC; Lee SH; Lim YJ; Yoon M; Park JG; Baek YB; Cho KO; Hong JW; Shin DJ; Kim SK
    J Leukoc Biol; 2022 Feb; 111(2):439-450. PubMed ID: 33884654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute graft-versus-host-like disease induced by transplantation of human activated natural killer cells into SCID mice.
    Xun C; Brown SA; Jennings CD; Henslee-Downey PJ; Thompson JS
    Transplantation; 1993 Aug; 56(2):409-17. PubMed ID: 8356598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attenuation of graft-versus-host-disease in NOD scid IL-2Rγ(-/-) (NSG) mice by ex vivo modulation of human CD4(+) T cells.
    Hilger N; Glaser J; Müller C; Halbich C; Müller A; Schwertassek U; Lehmann J; Ruschpler P; Lange F; Boldt A; Stahl L; Sack U; Oelkrug C; Emmrich F; Fricke S
    Cytometry A; 2016 Sep; 89(9):803-15. PubMed ID: 27560708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infusion of clinical-grade enriched regulatory T cells delays experimental xenogeneic graft-versus-host disease.
    Hannon M; Lechanteur C; Lucas S; Somja J; Seidel L; Belle L; Bruck F; Baudoux E; Giet O; Chantillon AM; Delvenne P; Drion P; Beguin Y; Humblet-Baron S; Baron F
    Transfusion; 2014 Feb; 54(2):353-63. PubMed ID: 23772685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD8-positive lymphocytes in graft-versus-host disease of humanized NOD.Cg-Prkdc(scid)Il2rg(tm1Wjl)/SzJ mice.
    Laing ST; Griffey SM; Moreno ME; Stoddart CA
    J Comp Pathol; 2015; 152(2-3):238-42. PubMed ID: 25670669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered donor P2X7 activity in human leukocytes correlates with P2RX7 genotype but does not affect the development of graft-versus-host disease in humanised mice.
    Adhikary SR; Geraghty NJ; Cuthbertson P; Sluyter R; Watson D
    Purinergic Signal; 2019 Jun; 15(2):177-192. PubMed ID: 31001750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tocilizumab increases regulatory T cells, reduces natural killer cells and delays graft-versus-host disease development in humanized mice treated with post-transplant cyclophosphamide.
    Sligar C; Cuthbertson P; Miles NA; Adhikary SR; Elhage A; Zhang G; Alexander SI; Sluyter R; Watson D
    Immunol Cell Biol; 2023 Aug; 101(7):639-656. PubMed ID: 37191045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling Human Graft-Versus-Host Disease in Immunocompromised Mice.
    Norelli M; Camisa B; Bondanza A
    Methods Mol Biol; 2016; 1393():127-32. PubMed ID: 27033222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.